Strides Shasun Limited (BSE: 532531, NSE: STAR) today announced its Q4 FY18 and FY 18 results
Performance Highlights – Q4 FY18 and FY 18 INR Mn
Particulars
Q1 FY18
Q2 FY18
Q3 FY 18
Q4 FY 18
FY18
FY17
YoY
Revenues
6,547
7,721
7,534
6,775
28,576
27,581
4%
EBITDA
834
1,129
1,401
1,005
4,369
6,027
(28%)
EBITDA %
13%
15%
19%
15%
15%
22%
(650 Bps)
Adj PAT
52**
1,304*
Adj EPS
0.6**
14.6*
*For FY18 - Adj for Stelis share of loss INR 144Mn, restructuring expense & others of INR 210Mn, CHC loss 446Mn
*For Q4FY18 - Adj for Stelis share of loss INR 43Mn, restructuring expense & others INR 36Mn, CHC loss 106 Mn
Arun Kumar, Group CEO and Managing Director, remarked, “The financial year 2017-18 was a difficult year for Strides. While we continue to build momentum with our strategy, our execution was far from satisfactory. We completed several of our corporate actions including exiting non-core operations and markets that did not add value to our overall goal of being a diversified B2C player globally”“We are particularly happy with the strategic progression at Arrow in Australia to become a leading and a profitable player. We are geared for a combination with Apotex to create an industry-leading position in Australia both by value and volume. We expect the transaction to achieve closure in the next two-quarters subject to regulatory approvals.”“In 2018-19 our clear focus will be on the improving the quality of growth which will deliver a strong bounce back in the second half of FY 19”
Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries.